World Journal of Urology

, Volume 34, Issue 3, pp 419–424 | Cite as

Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study

  • Ales Vidlar
  • Vladimir StudentJr.
  • Jitka Vostalova
  • Emilie FromentinEmail author
  • Marc Roller
  • Vilím Simanek
  • Vladimir Student
Original Article



Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust efficacy studies.


This 6-month, randomized, double-blind, placebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (Flowens™) on LUTS and uroflowmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an international prostate symptoms score (IPSS) score ≥8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary outcome measures included quality of life, bladder volume (Vol), maximum urinary flow rate (Q max), average urinary flow rate (Q ave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-specific antigen, selenium, interleukin 6, and C-reactive protein at 6 months.


After 6 months, subjects in both Flowens™ groups had a lower IPSS (−3.1 and −4.1 in the 250- and 500-mg groups, p = 0.05 and p < 0.001, respectively) versus the placebo group (−1.5), and a dose–response effect was observed. There were significant differences in Q max, Q ave, PVR, and Vol in the Flowens™ 500-mg group versus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers.


Flowens™ showed a clinically relevant, dose-dependent, and significant reduction in LUTS in men over 45.


Vaccinium macrocarpon Cranberry Lower urinary tract symptoms Benign prostatic hyperplasia IPSS 



Financial support from NATUREX-DBS is gratefully acknowledged. The cranberry powder (Flowens™) was supplied by NATUREX-DBS, SAGAMORE, MA 02561.

Conflict of interest

MR and EF are employed by NATUREX and NATUREX-DBS, respectively.

Ethical standard

Ethics Committee of the University Hospital and Faculty of Medicine and Dentistry, Palacky University in Olomouc, Czech Republic (reference 55/12).


  1. 1.
    McVary KT (2006) BPH: epidemiology and comorbidities. Am J Manag Care 12:S122–S128PubMedGoogle Scholar
  2. 2.
    Sarma AV, Wei JT (2012) Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 367:248–257CrossRefPubMedGoogle Scholar
  3. 3.
    American Urological Association (2010) American urological association guideline: management of benign prostatic hyperplasia (BPH). Accessed 4 June 2015
  4. 4.
    Elterman DS, Barkin J, Kaplan SA (2012) Optimizing the management of benign prostatic hyperplasia. Ther Adv Urol 4:77–83CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cheetham PJ (2013) Role of complimentary therapy for male LUTS. Curr Urol Rep 14:606–613CrossRefPubMedGoogle Scholar
  6. 6.
    Pappas E, Schaich KM (2009) Phytochemicals of cranberries and cranberry products: characterization, potential health effects, and processing stability. Crit Rev Food Sci Nutr 49:741–781CrossRefPubMedGoogle Scholar
  7. 7.
    Blumberg JB, Camesano TA, Cassidy A, Kris-Etherton P, Howell A, Manach C et al (2013) Cranberries and their bioactive constituents in human health. Adv Nutr 4:618–632CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Vidlar A, Vostalova J, Ulrichova J, Student V, Stejskal D, Reichenbach R et al (2010) The effectiveness of dried cranberries (Vaccinium macrocarpon) in men with lower urinary tract symptoms. Br J Nutr 104:1181–1189CrossRefPubMedGoogle Scholar
  9. 9.
    Pridgeon S, Harding C, Newton D, Pickard R (2007) Clinical evaluation of a simple uroflowmeter for categorization of maximum urinary flow rate. Indian J Urol 23:114–118CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ball AJ, Feneley RC, Abrams PH (1981) The natural history of untreated “prostatism”. Br J Urol 53:613–616CrossRefPubMedGoogle Scholar
  11. 11.
    Kolman C, Girman CJ, Jacobsen SJ, Lieber MM (1999) Distribution of post-void residual urine volume in randomly selected men. J Urol 161:122–127CrossRefPubMedGoogle Scholar
  12. 12.
    Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD (2008) Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 180:47–54CrossRefPubMedGoogle Scholar
  13. 13.
    Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A et al (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21:261–274CrossRefPubMedGoogle Scholar
  14. 14.
    Tacklind J, MacDonald R, Rutks I, Wilt TJ (2009) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev (2):CD001423. doi: 10.1002/14651858.CD001423
  15. 15.
    McNicholas T, Kirby R (2011) Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). Clinical Evidence;08:1801. Accessed 4 June 2015
  16. 16.
    Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J (2000) Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev (3):CD001043. doi: 10.1002/14651858
  17. 17.
    Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S (2007) A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine 14:568–579CrossRefPubMedGoogle Scholar
  18. 18.
    Nahata A, Dixit VK (2012) Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia 44(Suppl 1):396–409CrossRefPubMedGoogle Scholar
  19. 19.
    Spettel S, Chughtai B, Feustel P, Kaufman A, Levin RM, De E (2013) A prospective randomized double-blind trial of grape juice antioxidants in men with lower urinary tract symptoms. Neurourol Urodyn 32:261–265CrossRefPubMedGoogle Scholar
  20. 20.
    Takeda M, Araki I, Mochizuki T, Nakagomi H, Kobayashi H, Sawada N et al (2010) The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology of voiding dysfunction and pharmacological therapy. J Pharmacol Sci 112:121–127CrossRefPubMedGoogle Scholar
  21. 21.
    Caremel R, Oger-Roussel S, Behr-Roussel D, Grise P, Giuliano FA (2010) Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat. Eur Urol 58:616–625CrossRefPubMedGoogle Scholar
  22. 22.
    Kim MJ, Ohn J, Kim JH, Kwak HK (2011) Effects of freeze-dried cranberry powder on serum lipids and inflammatory markers in lipopolysaccharide treated rats fed an atherogenic diet. Nutr Res Pract 5:404–411CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51:1202–1216CrossRefPubMedGoogle Scholar
  24. 24.
    Wang W, Bergh A, Damber JE (2004) Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61:60–72CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Ales Vidlar
    • 1
  • Vladimir StudentJr.
    • 1
  • Jitka Vostalova
    • 2
  • Emilie Fromentin
    • 3
    Email author
  • Marc Roller
    • 4
  • Vilím Simanek
    • 2
  • Vladimir Student
    • 1
  1. 1.Department of UrologyUniversity HospitalOlomoucCzech Republic
  2. 2.Department of Medical Chemistry and Biochemistry, Faculty of Medicine and DentistryPalacky UniversityOlomoucCzech Republic
  3. 3.NATUREX-DBSSouth HackensackUSA
  4. 4.NATUREX SAAvignonFrance

Personalised recommendations